Aribio: Over 1,100 Patients Complete Dosing in AR1001 Phase 3 Trial

Aribio, a company specializing in the development of new drugs for degenerative brain diseases, announced that over 1,100 patients have completed dosing with its oral Alzheimer’s disease treatment candidate, AR1001, in the global Phase 3 clinical trial. Having met the target patient enrollment specified in the clinical trial protocol to ensure statistical power, the company plans to release topline data in September and subsequently submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).

Promotional image for Aribio's dementia treatment candidate AR1001's global Phase 3 clinical trial 'Polaris-AD'. Aribio

원본보기 아이콘

On April 28, Aribio revealed that more than 1,100 patients have completed dosing in the AR1001 global Phase 3 clinical trial (POLARIS-AD) being conducted across 13 countries. According to the company, reaching the target number of patients set in the clinical trial protocol fulfills the requirements for obtaining data necessary for statistical validity analysis.

Of the patients who completed one year of dosing in this trial, over 95% have enrolled in the ongoing open-label extension (OLE) study, with more than 1,000 patients currently continuing treatment. Aribio aims to complete dosing for a total of 1,535 patients by the end of June and plans to release topline results around September.

AR1001 is a small molecule compound, not an antibody, that crosses the blood-brain barrier (BBB) and acts within cells. Its mechanism involves inhibiting the overexpression of the enzyme PDE5 (phosphodiesterase-5), which breaks down cGMP, a neurotransmitter in brain cells.

Sharon Sha, Director of the Stanford Brain Science Institute and the lead investigator of the AR1001 global Phase 3 clinical trial, previously commented, "AR1001 is not just a simple anti-amyloid agent but a novel PDE5 inhibitor, a multi-mechanism drug that simultaneously addresses the complex pathology of Alzheimer’s disease."

Fred Kim, Head of Aribio’s U.S. branch, stated, "At a time when anti-amyloid-focused treatment strategies are being reassessed, AR1001’s multi-mechanism approach is drawing attention from both academia and the market. If significant results are confirmed in the Phase 3 trial, there is potential for AR1001 to become a first-line treatment for Alzheimer’s disease."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.